 BERKELEY, Calif., Nov. 17, 2021 GLOBE NEWSWIRE -- Caribou Biosciences, Inc. Nasdaq:CRBU, a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribous president and chief executive officer, will participate in the following upcoming investor conferences. 